Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1231.65
-13.85 (-1.11%)
< Home < Back

Dr. Reddy's gets USFDA’s nod for migraine treatment oral solution

Date: 07-05-2020

Dr. Reddy's Laboratories and its subsidiaries have received approval for their NDA, Elyxyb (celecoxib oral solution 25 mg/mL) from the US Food and Drug Administration (USFDA).

ELYXYB (previously known as DFN-15) is indicated for the acute treatment of migraine with or without aura in adults. ELYXYB is the latest product emerging from Dr. Reddy's portfolio of successful acute migraine treatments. The company is working to commercialize this product through partners.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.